U.K.-based artificial intelligence (AI) software developer Motilent has received U.S. Food and Drug Administration (FDA) 510(k) clearance for GIQuant, an MR image analysis application for evaluating gastrointestinal function in digestive diseases.
The postprocessing software, which is initially being focused on Crohn's disease, is designed to measure intestinal motility and treatment response on standard MRI exams, according to the vendor. It's already been in clinical use at sites in the U.K., such as Great Ormond Street Hospital and Frimley Park Hospital NHS Foundation Trust.
Motilent said it would roll out GIQuant in the U.S. in collaboration with partner Nuance Communications. The firm showcased GIQuant in its debut appearance at the recent annual RSNA meeting in Chicago.
